PLUVICTO—now available for PSMA+ mCRPC before chemotherapy
If you’ve had hormone therapy, it may be time for PLUVICTO. Learn more about eligibility by clicking the link below.
After hormone therapy, men with PSMA+ mCRPC who received PLUVICTO saw:
More time without their cancer progressing, with a median of 9.3 months vs 5.6 months with a second hormone therapy | Their tumors shrink or disappear, 49% of the time vs 14% with a second hormone therapy |
Ask about PLUVICTO. It’s not chemotherapy. It’s the FIRST and ONLY PSMA-targeted radioligand therapy.
Find out if PLUVICTO could be the next step for you or a loved one. Follow these links to explore why: | If you or a loved one has started on PLUVICTO, here's what you need to know: |
Interested in receiving information about PLUVICTO?
PLUVICTO® Pulse provides educational support and materials for those considering and starting on treatment.
Watch the video to see what more time without progression could mean for you.
mCRPC, metastatic castration-resistant resistant prostate cancer; PSMA+, prostate-specific membrane antigen positive.